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Introduction
Juvenile Systemic Sclerosis (JSS) is characterized by Ray-
naud’s phenomenon (RP) and digital ulcers (DU). Con-
ventional therapy includes calcium channel blockers
(CCB) A growing number of vasodilators is available for
treatment of refractory patients but there is no clear evi-
dence of the best option. To aid clinical decision-mak-
ing, a consensus of expert was undertaken.
Objectives
To identify the best therapeutic options and define the
sequence of 2nd line vasodilators for RP and DU.
Methods
Steps in the process of consensus were: a) Identification
of expert panel (EP) members, b) Identification of 2nd
line vasodilators c) identification of outcome measures
to define RP and DU improvement, d) systematic litera-
ture review; e) summary report of the latest scientific
evidence f) expert consensus meeting; g) rating of the
strength of evidence. RAND/UCLA appropriateness
method was used for rating the medical decision: items
were rated on a 9-point scale on each drug option.
There were two scoring rounds: first: anonymous and
independent rating of the appropriateness of vasodila-
tors based on scientific evidence and best clinical judg-
ment. Differences in scoring were discussed at a face-to-
face meeting, followed by a second rating round. Con-
sensus was reached on appropriate/inappropriateness.
Results
The EP included 10 physicians from a tertiary center
who are involved in the care of patients with JSS: 3
pediatric rheumatologists, 2 dermatologists, 1 pediatri-
cian, 1 gastroenterologist, 1 nephrologist, 1 nutricionist,
1 pharmacologist, and a moderator. The EP identified 4
drugs for analysis: bosentan, iloprost, sildenafil, and tre-
postinil. Outcome measures were selected according to
the literature references and EP judgment. RP improve-
ment definition: ≥ 30% improvement according to the
physician (in a visual analogue scale, VAS) and ≥ 30%
improvement in at least 2 patient-related domains (pain
or function). Patient domains were: a) number of epi-
sodes, b) pain in a VAS, c) function (impaired activity of
daily living, VAS), d) RP episodes average duration (in
minutes). DU improvement definition: a favorable
change in all physician- and patient-related domains:
patient’s domains: a) pain (VAS) b) function (VAS); phy-
sician’s domains: a) ulcer activity (VAS) b) horizontal
and transverse DU diameter (in mm). Systematic litera-
ture review was performed independently by 5 EP mem-
bers and guided by the moderator. All articles in
English were eligible. Data bases included pubmed and
Cochrane. The search strategy included all relevant
terms: bosentan, iloprost, sildenafil, trepostinil, RP, DU,
combined in different sets of keywords. The summary
report of the scientific evidence included 25 articles.
Ranking of papers according to the strength of evidence
showed: 1a (1 paper), 1b (7), 2b (2), 3b (2), 4(8), 5(5).
After second scoring round: 1st appropriate indication
Iloprost; 2nd bosentan, 3rd sildenafil; 4th trepostinil.
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Conclusion
The EP reached a consensus on vasodilator drugs, pro-
viding direction for common dilemmas in the pharma-
cologic treatment of RP and DU in refractory patients.
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